Paul Riegelhaupt, MD, PhD

Highlights

1
Nature communications · 2023
CNCrina Nimigean PRPaul Riegelhaupt
PMID: 36841877PMCID: PMC9968290DOISenior author54 citations
2
Proceedings of the National Academy of Sciences of the United States of America · 2025
PRPaul Riegelhaupt
PMID: 40178898PMCID: PMC12002230DOISenior author4 citations
3
eLife · 2020
CNCrina Nimigean PRPaul Riegelhaupt
PMID: 33345771PMCID: PMC7781597DOISenior author25 citations

18

2 grants

Co-I
Human(h) HCN1-selective nanobodies for use in the development of novel, non-opioid antihyperalgesics for the treatment of neuropathic pain
National Institute of Neurological Disorders and Stroke · 2026–2028
R61NS147892-01
PI
Molecular mechanisms of Tandem Pore potassium channel gating and regulation
National Institute of General Medical Sciences · 2022–2027Equipment· 2 renewals
R01GM145918-02S1

Completed grants (3)

PI
Mechanisms of Volatile Anesthetic Modulation of Tandem Pore Potassium Channels
National Institute of General Medical Sciences · 2019–2024Career
K08GM132781-05
PI
Fatty acid pharmacology of neuroprotective K2P channels
Society For Neuroscience · 2021–2022
SN 220081-01
PI
Structural and Functional Characterization of the TREK1 K2P Potassium Channel, A Target for Chronic Pain Therapy
Foundation for Anesthesia Education & Research · 2017–2019
FAER-182483-2

NIH Grant Awarded to Continue Non-Opioid Pain Medication Research
November 4, 2026
The grant will enable researchers to study a new approach for delivering an experimental non-opioid pain medication, called BP4L-18:1:1, to relieve neuropathic pain.
Weill Cornell Launches Physician-Scientist Program to Support Early to Mid-Career Faculty
November 4, 2026
The initiative provides physician-scientists with extended periods of dedicated time to pursue research that is financially compartmentalized from their clinical responsibilities.

3